Современные подходы к консервативной терапии взрослых пациентов с бронхоэктазами
https://doi.org/10.18093/0869-0189-2019-29-1-71-86
Аннотация
Бронхоэктазы (БЭ) – достаточно распространенное хроническое бронхолегочное заболевание, однако в настоящее время в мире четкие клинические рекомендации по лечению этого заболевания не разработаны, а опубликованная информация не позволяет однозначно оценить эффективность используемых сегодня методов консервативной терапии БЭ. В то же время основной целью ведения пациентов с БЭ является предотвращение обострений, уменьшение выраженности симптомов, улучшение качества жизни и замедление прогрессирования заболевания. В данном обзоре проанализирована доступная информация об эффективности и целесообразности применения отдельных групп лекарственных препаратов у пациентов с БЭ, а также немедикаментозных методов улучшения бронхиального клиренса.
Об авторах
С. Ю. Чикина
Первый Московский государственный медицинский университет имени И.М.Сеченова Министерства здравоохранения Российской Федерации
Россия
Россия
Чикина Светлана Юрьевна – кандидат медицинских наук, ассистент кафедры пульмонологии.
119991, Москва, ул. Трубецкая, 8, стр. 2; тел.: (916) 116-04-03.
С. Н. Авдеев
Первый Московский государственный медицинский университет имени И.М.Сеченова Министерства здравоохранения Российской Федерации; Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства
Россия
Россия
Авдеев Сергей Николаевич – доктор медицинских наук, член-корреспондент Российской академии наук, профессор, заведующий кафедрой пульмонологии Первого МГМУ имени И.М.Сеченова МЗ РФ, руководитель клинического отдела НИИ пульмонологии Федерального медико-биологического агентства.
119991, Москва, ул. Трубецкая, 8, стр. 2; 115682, Москва, Ореховый бульвар, 28; тел.: (495) 708-35-76.
Список литературы
1. Bilton D., Jones A.L. Bronchiectasis: epidemiology and causes. In: Floto R.A., Haworth C.S., eds. Bronchiectasis. Eur. Respir. Monograph. 2011; 52: 239–247. DOI: 10.1183/1025448x.erm5210.
2. Vendrell M., de Gracia J., Olveira C. et al. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch. Bronconeumol. 2008; 44 (11): 629–640 (in Spanish).
3. Chalmers J.D., Aliberti S., Blasi F. Management of bronchiectasis in adults. Eur. Respir. J. 2015; 45: 1446–1462. DOI: 10.1183/09031936.00119114.
4. Loebinger M.R., Wells A.U., Hansell D.M. et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur. Respir. J. 2009; 34: (4): 843–849. DOI: 10.1183/09031936.00003709.
5. McDonnell M.J., Aliberti S., Goeminne P.C. et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016; 71 (12): 1110–1118. DOI: 10.1136/thoraxjnl-2016-208481.
6. Finch S., McDonnell M.J., Abo-Leyah H. et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 2015; 12 (11): 1602–1611. DOI: 10.1513/AnnalsATS.201506-333OC.
7. Snijders D., Fernandez Dominguez B., Calgaro S. et al. Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence? Int. J. Immunopathol. Pharmacol. 2015; 28 (2): 150–159. DOI: 10.1177/0394632015584724.
8. McDonnell M.J., Aliberti S., Goeminne P.C. et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir. Med. 2016; 4 (12): 969–979. DOI: 10.1016/S2213-2600(16)30320-4.
9. Du Q., Jin J., Liu X., Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: A systematic review and meta-analysis. PLoS One. 2016; 11 (3): e0150532. DOI: 10.1371/journal.pone.0150532.
10. Navaratnam V., Muirhead C.R., Hubbard R.B., De Soyza A. Critical care admission trends and outcomes in individuals with bronchiectasis in the UK. QJM. 2016; 109 (8): 523–526. DOI: 10.1093/qjmed/hcv206.
11. Navaratnam V., Millett E.R., Hurst J.R. et al. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax. 2017; 72 (2): 161–166. DOI: 10.1136/thoraxjnl-2015-208188.
12. Chalmers J.D., Goeminne P., Aliberti S. et al. The bronchiectasis severity index. An international derivation and validation study. Am. J. Respir. Crit. Care Med. 2014; 189 (5): 576–585. DOI: 10.1164/rccm.201309-1575OC.
13. Chalmers J.D., Smith M.P., McHugh B.J. et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2012; 186 (7): 657–665. DOI: 10.1164/rccm.201203-0487OC.
14. Sheehan R.E., Wells A.U., Copley S.J. et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur. Respir. J. 2002; 20 (3): 581–587. DOI: 10.1183/09031936.02.00284602.
15. Aliberti S., Lonni S., Dore S. et al. Clinical phenotypes in adult patients with bronchiectasis. Eur. Respir. J. 2016; 47 (4): 1113–1122. DOI: 10.1183/13993003.01899-2015.
16. Kapur N., Masters I.B., Chang A.B. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: What influences lung function stability? Chest. 2010; 138: 158–164.
17. Chalmers J.D., Aliberti S., Polverino E. et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res. 2016; 2: 00081-2015.
18. Lee A.L., Burge A.T., Holland A.E. Airway clearance techniques for bronchiectasis. Cochrane Database Syst. Rev. 2015; (11): CD008351. DOI: 10.1002/14651858.CD008351.pub3.
19. Muñoz G., de Gracia J., Buxó M. et al. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. Eur. Respir. J. 2018; 51 (1): pii: 1701926. DOI: 10.1183/13993003.01926-2017.
20. Wong C., Sullivan C., Jayaram L. ELTGOL airway clearance in bronchiectasis: laying the bricks of evidence. Eur. Respir. J. 2018; 51 (1): pii: 1702232. DOI: 10.1183/13993003.02232-2017.
21. Lee A.L., Burge A.T., Holland A.E. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst. Rev. 2017; (9): CD011699. DOI: 10.1002/14651858.CD011699.pub2.
22. Polverino E., Goeminne P.C., McDonnell M.J. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 2017; 50: 1700629. DOI: 10.1183/13993003.00629-2017.
23. Tarrant B. J., Le Maitre C., Romero L. et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis. Respirology. 2017; 22: 1084–1092. DOI: 10.1111/resp.13047.
24. Hart A., Sugumar K., Milan S.J. et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev. 2014; (5): CD002996. DOI: 10.1002/14651858.CD002996.pub3.
25. Kellett F., Robert N.M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 2011; 105 (12): 1831–1835. DOI: 10.1016/j.rmed.2011.07.019.
26. Nicolson C.H., Stirling R.G., Borg B.M. et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir. Med. 2012; 106: 661–667.
27. Kellett F., Redfern J., Niven R.M. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir. Med. 2005; 99 (1): 27–31.
28. Herrero-Cortina B., Alcaraz V., Vilaró J. et al. Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial. J. Aerosol Med. Pulm. Drug Deliv. 2018; 31 (5). DOI: 10.1089/jamp.2017.1443.
29. Máiz L., Girón R.M., Prats E. et al. Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients. Ther. Adv. Respir. Dis. 2018; 12: 1753466618787385. DOI: 10.1177/1753466618787385.
30. Bilton D., Tino G., Barker A.F. et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014; 69: 1073–1079.
31. Yang C., Chilvers M., Montgomery M., Nolan S.J. Dornase alfa for cystic fibrosis. Cochrane Database Syst. Rev. 2016; (4): CD001127. DOI: 10.1002/14651858.CD001127.pub3.
32. O’Donnell A.E., Barker A.F., Ilowite J.S., Fick R.B. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998; 113 (5): 1329–1334.
33. Wills P.J., Wodehouse T., Corkery K. et al. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am. J. Respir. Crit. Care Med. 1996; 154 (2): 413–417. DOI: 10.1164/ajrccm.154.2.8756815.
34. Hassan J.A., Saadiah S., Roslan H., Zainudin B.M. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology. 1999; 4 (4): 423–426.
35. Jeong H.J., Lee H., Carriere K.C. et al. Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 2757–2764.
36. Tsang K.W., Ho P.L., Lam W.K. et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am. J. Respir. Crit. Care Med. 1998; 158 (3): 723–727.
37. Martínez-García M.A., Perpiñá-Tordera M., Román-Sánchez P., Soler-Cataluña J.J. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir. Med. 2006; 100 (9): 1623–1632.
38. Kapur N., Petsky H.L., Bell S. et al. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst. Rev. 2018; (5): CD000996. DOI: 10.1002/14651858.CD000996.pub3.
39. Wei P., Yang J.W., Lu H.W. et al. Combined inhaled corticosteroid and long-acting β2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: An observational study. Medicine (Baltimore). 2016; 95 (42): e5116.
40. Martínez-García M.Á.,Soler-Cataluña J.J., Catalán-Serra P. et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012; 141 (2): 461–468. DOI: 10.1378/chest.11-0180.
41. Lee J.K., Lee J., Park S.S. et al. Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis. Int. J. Tuberc. Lung Dis. 2014; 18 (3): 363–370. DOI: 10.5588/ijtld.13.0255.
42. Jang E.J., Lee C.H., Yoon H.I. et al. Association between inhaler use and risk of haemoptysis in patients with non-cystic fibrosis bronchiectasis. Respirology. 2015; 20 (8): 1213–1221. DOI: 10.1111/resp.12618.
43. Pasteur M.C., Bilton D., Hill A.T. et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65 (Suppl. 1): i1–58. DOI: 10.1136/thx.2010.136119.
44. McShane P.J., Naureckas E.T., Tino G., Strek M.E. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 647–656. DOI: 10.1164/rccm.201303-0411CI.
45. Dhand R. The rationale and evidence for use of inhaled antibiotics to control pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J. Aerosol Med. Pulm. Drug Deliv. 2018; 31 (3): 121–138. DOI: 10.1089/jamp.2017.1415.
46. Brodt A.M., Stovold E., Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur. Respir. J. 2014; 44 (2): 382–393. DOI: 10.1183/09031936.00018414.
47. Paredes Aller S., Quittner A.L., Salathe M.A., Schmid A. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis–experiences from recent clinical trials. Expert. Rev. Respir. Med. 2018; 3: 1–14. DOI: 10.1080/17476348.2018.1503540.
48. Авдеев С.Н., Карчевская Н.А. Первый опыт использования небулизированного тобрамицина при обострении бронхоэктазов. Пульмонология. 2011; (4): 133–138.
49. Овчаренко С.И., Капустина В.А. Эффективность и безопасность небулизированного тиамфеникола глицината ацетилцистеината в лечении хронических заболеваний органов дыхания. Практическая медицина. 2013; 5 (74): 102–105.
50. Haworth C.S., Foweraker J.E., Wilkinson P. et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2014; 189 (8): 975–982. DOI: 10.1164/rccm.201312-2208OC.
51. Murray M.P., Govan J.R., Doherty C.J. et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2011; 183 (4): 491–499. DOI: 10.1164/rccm.201005-0756OC.
52. De Soyza A., Aksamit T., Bandel T.J. et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2018; 51 (1): pii: 1702052. DOI: 10.1183/13993003.02052-2017.
53. Aksamit T., De Soyza A., Bandel T.J. et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2018; 51 (1): pii: 1702053. DOI: 10.1183/13993003.02053-2017.
54. Chotirmall S.H., Chalmers J.D. RESPIRE: breathing new life into bronchiectasis. Eur. Respir. J. 2018; 51 (1): pii: 1702444. DOI: 10.1183/13993003.02444-2017.
55. Bilton D., Serisier D.J., De Soyza A.T. et al. Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2011; 38: 1925.
56. Serisier D.J., Bilton D., De Soyza A. et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013; 68 (9): 812–817. DOI: 10.1136/thoraxjnl-2013-203207.
57. Haworth C., Wanner A., Froehlich J. et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: Results from two parallel phase III trials (ORBIT-3 and -4). Am. J. Respir. Crit. Care Med. 2017; 195: A7604.
58. Barker A.F., O'Donnell A.E., Flume P. et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir. Med. 2014; 2 (9): 738–749. DOI: 10.1016/S2213-2600(14)70165-1.
59. Drobnic M.E., Suñé P., Montoro J.B. et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with pseudomonas aeruginosa. Ann. Pharmacother. 2005; 39: 39–44.
60. Barker A.F., Couch L., Fiel S.B. et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 481–485.
61. Zimmermann P., Ziesenitz V.C., Curtis N., Ritz N. The immunomodulatory effects of macrolides – a systematic review of the underlying mechanisms. Front. Immunol. 2018; 9: 302. DOI: 10.3389/fimmu.2018.00302.
62. Kelly C., Chalmers J.D., Crossingham I. et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst. Rev. 2018; (3): CD012406. DOI: 10.1002/14651858.CD012406.pub2.
63. Wong C., Jayaram L., Karalus N. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 660–667. DOI: 10.1016/S0140-6736(12)60953-2.
64. Altenburg J., de Graaff C.S., Stienstra Y. et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013; 309 (12): 1251–1259. DOI: 10.1001/jama.2013.1937.
65. Serisier D.J., Martin M.L., McGuckin M.A. et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013; 309 (12): 1260–1267. DOI: 10.1001/jama.2013.2290.
66. Li W., Qin Z., Gao J. et al. Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison. Chron. Respir. Dis. 2018; 12: 1479972318790269. DOI: 10.1177/1479972318790269.
67. Asintam P., Kiranantawat N., Juthong S. Can roxithromycin improve quality of life in bronchiectatic patients? Eur. Respir. J. 2012; 40: P2168.
68. Lourdesamy A., Muthukumaru U. Efficacy of azithromycin in the treatment of bronchiectasis. Respirology. 2014; 19 (8): 1178–1182. DOI: 10.1111/resp.12375.
69. Sadigov A.S., Mammadov G.T. Azythromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease? Am. J. Respir. Crit. Care Med. 2013; 187: A3512.
70. Haworth C.S., Bilton D., Elborn J.S. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir. Med. 2014; 108 (10): 1397–1408. DOI: 10.1016/j.rmed.2014.09.005.
71. Juthong S., Eiamsa-ard S. Late-breaking abstract: The effects of roxithromycin as anti-inflammatoy agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study. Eur. Respir. J. 2011; 38 (Suppl. 55): 4496.
72. Bonaiti G., Pesci A., Marruchella A. et al. Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis. Biomed. Res. Int. 2015; 2015: 197950. DOI: 10.1155/2015/197950.
73. Olivieri D., Ciaccia A., Marangio E. et al. Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo. Respiration. 1991; 58 (3–4): 117–121.
74. Wilkinson M., Sugumar K., Milan S.J. et al. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2014; (5): CD001289. DOI: 10.1002/14651858.CD001289.pub2.
75. Crisafulli E., Coletti O., Costi S. et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin. Ther. 2007; 29 (9): 2001–2009.
Рецензия
Для цитирования:
Чикина С.Ю., Авдеев С.Н. Современные подходы к консервативной терапии взрослых пациентов с бронхоэктазами. Пульмонология. 2019;29(1):71-86. https://doi.org/10.18093/0869-0189-2019-29-1-71-86
For citation:
Chikina S.Yu., Avdeev S.N. Current approaches to pharmacological treatment of adult patients with bronchiectasis. PULMONOLOGIYA. 2019;29(1):71-86. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-1-71-86
Просмотров:
1583
Послать статью по эл. почте 